Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BI 764532 + Topotecan |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BI 764532 | BI-764532|BI764532|Obrixtamig | CD3 Antibody 119 DLL3 Antibody 10 | BI 764532 is a bispecific antibody targeting DLL3 and CD3, which may lead to activation of T-cell-mediated immune response against DLL3-expressing tumor cells (J Clin Oncol 41, 2023 (suppl 16; abstr 8502)). | |
| Topotecan | Hycamtin | Topotecan Hcl | Topotecan binds to topoisomerase I and stablizes complexes with DNA, resulting in decreased repair of DNA single-strand breaks, and potentially leading to cell death (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05990738 | Phase I | BI 764532 + Topotecan | DAREON-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With Topotecan | Recruiting | USA | POL | GBR | FRA | DEU | 0 |